These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 17439382

  • 1. Carotid artery intima-media thickness after raloxifene treatment.
    Mack WJ, Dhungana B, Dowsett SA, Keech CA, Feng M, Li Y, Hodis HN.
    J Womens Health (Larchmt); 2007 Apr; 16(3):370-8. PubMed ID: 17439382
    [Abstract] [Full Text] [Related]

  • 2. Raloxifene slows down the progression of intima-media thickness in postmenopausal women.
    Colacurci N, Fornaro F, Cobellis L, De Franciscis P, Torella M, Sepe E, Arciello A, Cacciapuoti F, Paolisso G, Manzella D.
    Menopause; 2007 Apr; 14(5):879-84. PubMed ID: 17667145
    [Abstract] [Full Text] [Related]

  • 3. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators.
    J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
    [Abstract] [Full Text] [Related]

  • 4. Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women.
    Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto H, Koizumi A, Kanai H, Araki Y, Itoh T, Iwasaki T, Sawada Y, Saito Y, Kumakura H, Takayama Y, Kanda T, Murakami M, Sakamaki T, Kurabayashi M.
    Int Heart J; 2010 Jan; 51(1):60-7. PubMed ID: 20145354
    [Abstract] [Full Text] [Related]

  • 5. Inverse correlation of carotid intima-media thickness with raloxifene serum levels in osteoporosis.
    Lušin TT, Mrhar A, Marc J, Trontelj J, Zavratnik A, Zegura B, Pfeifer M, Ostanek B.
    Wien Klin Wochenschr; 2014 Jul; 126(13-14):403-8. PubMed ID: 24842749
    [Abstract] [Full Text] [Related]

  • 6. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K.
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [Abstract] [Full Text] [Related]

  • 7. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis.
    Celiloglu M, Aydin Y, Balci P, Kolamaz T.
    Menopause; 2009 Oct; 16(4):689-93. PubMed ID: 19240658
    [Abstract] [Full Text] [Related]

  • 8. Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women.
    Tremollieres FA, Cigagna F, Alquier C, Cauneille C, Pouilles J, Ribot C.
    Atherosclerosis; 2000 Nov; 153(1):81-8. PubMed ID: 11058702
    [Abstract] [Full Text] [Related]

  • 9. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 10. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
    Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML, METEOR Study Group.
    JAMA; 2007 Mar 28; 297(12):1344-53. PubMed ID: 17384434
    [Abstract] [Full Text] [Related]

  • 11. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
    Chmel R, Rob L, Strnad P.
    Ceska Gynekol; 2002 Jul 28; 67(4):187-91. PubMed ID: 12373918
    [Abstract] [Full Text] [Related]

  • 12. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
    Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG.
    Breast Cancer Res Treat; 2001 Jan 28; 65(2):125-34. PubMed ID: 11261828
    [Abstract] [Full Text] [Related]

  • 13. Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women.
    Cox DA, Sarkar S, Harper K, Barrett-Connor E.
    Curr Med Res Opin; 2004 Jul 28; 20(7):1049-55. PubMed ID: 15265250
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety of 3-year raloxifene treatment in Japanese postmenopausal women aged 75 years or older with osteoporosis: a postmarketing surveillance study.
    Takeuchi Y, Hamaya E, Taketsuna M, Sowa H.
    Menopause; 2015 Oct 28; 22(10):1134-7. PubMed ID: 25756692
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Results of international clinical trials with raloxifene].
    Agnusdei D, Liu-Léage S, Augendre-Ferrante B.
    Ann Endocrinol (Paris); 1999 Sep 28; 60(3):242-6. PubMed ID: 10520416
    [Abstract] [Full Text] [Related]

  • 18. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
    Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, Anderson PW.
    Clin Ther; 2003 Mar 28; 25(3):919-30. PubMed ID: 12852708
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.